Key facts
- Pepticom’s last known valuation is $35.4M (Jan 2025).
- It has raised $11.6M; the latest was Later Stage VC ($6.6M) in Jan 2025.
- Notable investors include BioGiv Excubator, Galia Kut, The Chartered Group, Yissum.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Pepticom
- ·The full record, as it builds
Funding rounds
No funding rounds for Pepticom are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Pepticom
Developer of a drug discovery platform designed to accelerate and optimize peptide-based therapeutic development. The company's platform utilizes artificial intelligence to create peptides with specificity, stability, and therapeutic potential by integrating various types of amino acid building blocks, enabling the pharmaceutical industry to streamline research, enhance efficiency, and reduce costs in addressing complex medical challenges.
- Sector
- Healthcare
- HQ
- Jerusalem, Israel
- Founded
- 2011
- Employees
- 15
- Website
- pepticom.com/
- Ownership
- Privately Held (backing)
Pepticom doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Pepticom shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Pepticom in its N-PORT filings yet. We sweep new filings monthly.